May 9NuvOx Appoints Dr. Robert King to SABTucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a...
May 9NuvOx Technology Featured in Prominent Peer Review JournalTucson, AZ, April 19, 2022 -- https://www.pr.com/press-release/859633 NuvOx Pharma’s technology, which is developed as a first-in-class...
May 9NuvOx Finalizes Facility Certification, Poising for Phase IIb TrialsTucson, AZ, April 17, 2022 -- https://www.pr.com/press-release/859467 NuvOx Pharma, a clinical stage biotechnology company developing a...
Mar 4NuvOx Receives Notice from the Breakthrough DOD Award for its Immuno-Oncology ProgramOn February 11th, 2022,-- https://www.pr.com/press-release/859467 NuvOx Pharma received notice from the Department of Defense (DOD)...
Feb 10NuvOx to Participate in the BIO CEO Investor ConferenceTucson, AZ, February 10, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
Jan 12NuvOx to Present at Various Bio Forums in JPM Week Tucson, AZ, January 7, 2022 Tucson, AZ, January 7, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
Oct 15, 2021NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in StrokeTucson, AZ, October 12, 2021 --(PR.com)-- NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small...
Sep 9, 2021NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of ImmunotherapyTucson, AZ, September 09, 2021 --(PR.com)-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive...
Jul 29, 2021NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they...
Jul 23, 2021NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating CancerTucson, AZ, July 23, 2021 --(PR.com)-- NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has...
May 27, 2021Tucson's NuvOx adds plant to make drugs in-houseA tandem of homegrown Tucson drug-development companies plans to make its own drugs for testing at a new manufacturing plant — and...
Apr 30, 2021NuvOx Completes Construction of Expanded Manufacturing FacilityA new GMP production facility including an ISO 5 cleanroom has been constructed and has initiated operations. Click here to read more...
Dec 28, 2020NuvOx Pharma Announces Appointment of Jon S. Saxe to Its Board of Directors"We are honored and excited to have Jon Saxe join our board," said Evan Unger MD, President and CEO of NuvOx. "His broad knowledge of the...
Jul 15, 2020Hunniwell Lake Ventures Spotlights NuvOxHunniwell Lake Ventures interviews NuvOx Co-founder and CEO, Evan Unger MD.
Jun 30, 2020Health Canada Allows Phase IIa Clinical Trial in COVID-19 Patients with Respiratory Failure Health Canada allows a Phase IIa Trial in COVID-19 patients with Respiratory Failure
Dec 7, 2019NuvOx Expands Production LineNuvOx Pharma is breaking ground on an addition to its manufacturing facility. Read full story
Feb 28, 2019NuvOx Pharma’s NanO2 Shows Positive Results in Phase Ib/II Stroke TrialPositive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A...
Oct 18, 2017NuvOx Wins TechConnect Defense Innovation AwardNuvOx was awarded the TechConnect Defense Innovation Award based on the potential impact the technology will have on national security.
Oct 11, 2017NuvOx Pharma wins AZBio Fast Lane AwardNuvOx was honored with the AZBIO Fast Lane Award for the company's many achievements in the last 18 months.
Sep 29, 2017National Cancer Institute Grants $3M to NuvOx Pharma for Phase II Clinical Trial in Brain CancerThe NCI Grants $3M to NuvOx for a Phase II clinical trial in the brain cancer, glioblastoma.